Women under HIV siege bolster microbicide research by Bateman, Chris
South African women, facing the brunt
of the HIV/AIDS onslaught, are
clamouring to help test a cutting-edge
microbicide that has already proved
effective in preventing HIV infections in
animals.
Regarded as being at the forefront of
microbicide research worldwide, the
trials began in March 2004 and 1 800
women have qualified to take part so
far (out of 6 800 targeted for enrolment
by September 2005).
Queueing up
Dr Sumen Govender, the national
clinical study manager, reported
unusually long lines of people outside
participating clinics in Soshanguve,
Pretoria, Isipingo in KwaZulu-Natal
and Gugulethu near Cape Town. Just 10
months into the 30-month trial of the
seaweed-based gel called Carraguard,
recruiters were still drawing large
crowds to presentations at church halls,
clinics, schools and community centres.
‘Many women participating in the
previous phase 2 trial (the expanded
safety trial) didn’t want it to end, they
were so into it. It just shows how they
view the role of microbicides in the
future. It’s something that will actually
change their lives and they really value’,
Govender said.
A major bonus was that hundreds of
women had continued into the current
phase 3 of the trials, which helped his
120-person team in the field reinforce
the vital issue of compliance.
The New York-based Population
Council’s Centre for Biomedical
Research is underwriting this and
several other microbicide trials.
According to its vice-president, Dr Elof
Johansson, prospects for success are
‘excellent’.
He told Izindaba that globally the only
other microbicide that has reached
phase 3 clinical trials is a product called
Savvy, a detergent that destroys the
virus by changing its environment. It is
currently being tested in Ghana, while
Nigeria will join in the trial later this
year (2005).
However, Savvy’s major drawback is
that, unlike Carraguard, it creates
irritation in the vagina.
Compliance crucial
Both Johansson and Govender admitted
that compliance could prove to be the
Achilles’ heel of the local study, as it is
crucial in achieving an acceptable
outcome. ‘It’s based a lot on trust, but
we’ve turned every stone we can,
according to the knowledge we
currently have,’ said Govender.
Clinic counsellors impressed upon
participants that they had to use the gel
‘each and every time’ they had sex.
They asked probing, behavioural
questions during all follow-up sessions.
Participants receive an extensive
briefing beforehand and have to return
all used and unused gel dispensers, so
that the trial team can take stock of
what was given out and what was
returned.
Reason for hope
Govender said the main reason for his
optimism was that ‘loss to follow-up’
levels among trial participants currently
stood at less than 3%. ‘This stands us in
good stead when it comes to women
staying in the trial.’
Tools for monitoring behaviour
included using a dye that indicated
when an applicator had been used, and
booklets, pamphlets and posters that
were first introduced by community
liaison officers at the pre-enrolment
stage.
Johansson said the best reason for
optimism around the gel was that in
animal studies, models that mimicked
the HIV infection had proved highly
effective in preventing transmission.
Results in animals showed that the gel
protected monkeys against SIV, rats
against herpes simplex, while a special
system in which tissue from the human
vagina was transplanted into animals
had also proved successful. ‘All showed
that transmission was prevented,’
Johansson said.
While the actual mechanism of how
the microbicides work remains
unknown, clinical trials in a laboratory
setting show that Carraguard carries a
highly negative charge which repels the
highly positively-charged viral
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A major bonus was that
hundreds of women had
continued into the current
phase 3 of the trials, which
helped his 120-person team
in the field reinforce the
vital issue of compliance.
WOMEN UNDER HIV SIEGE BOLSTER MICROBICIDE
RESEARCH
100 years ago:
Sir: The following may be interesting to your readers; Mrs L, age about 40, multipara, had been a patient of mine for
several years, during which she had had two miscarriages. Was very neurotic, and frequently complained of bladder
trouble, though the urine whenever examined was always normal. She told me that at her last full term labour she had
severe fits. In August of this year I attended her in labour in the Maternity Ward of the Kimberley Hospital. Everything
was going on very satisfactorily, though labour was progressing rather slowly. The urine was free from albumen the
morning labour commenced. In the afternoon I was informed by the nurse that she had had a convulsive attack, but that
it was not very prolonged. Half an hour afterwards she had a severe and prolonged eclamptic seizure. I got Dr Briggs to
administer chloroform, and easily delivered with forceps. The convulsions at once ceased, and there was no recurrence.
Mentioning to Dr Briggs that this was a case of eclampsia without albuminuria, he suggested that it was possibly a case
of albuminuria coming on rapidly during labour. To test this, some urine was at once drawn off by catheter, and was
found to contain half albumen (sic). Next morning the albumen  was greatly diminished, and in two days it was gone. I
think the case worthy of record, as, had it not been for Dr Briggs's suggestion, I should certainly have regarded it as
non-albuminuric, as at no time previous to labour or even early in labour was albumen present. Yours, etc., ARNOLD H
WATKINS.  
50 years ago: Diagnosis of acute appendicitis
For the past 50 years medical students have been harangued by their teachers on the classic picture of acute
appendicitis. In spite of this, mistakes and delay in diagnosis have continued. Many of these have no doubt been due to
human failing, but the outstanding reason has been the blind and continued servility of generations of teachers to the
concepts of the classic descriptions. One point has from time to time been emphasised by those observers who remain
unbound by tradition when it degenerates into rabbinical dogma: the majority of cases of acute appendicitis do fall
more or less accurately into the timeworn descriptions, but a very significant minority do not. In this respect figures do
not provide any very useful information, but roughly one might say that something like 30% of cases depart in some
significant way from the text-book picture of the disease. It is in this group that the vast majority of diagnostic errors
occur. 
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envelope. This deactivates the virus and
prevents it from entering the cells.
The gel coats the surface of the vagina
and forms a barrier, preventing the cells
from moving into the epithelium of the
vagina.
Govender emphasised that
Carraguard was not a contraceptive or a
spermicide, although further work on a
dual-purpose gel could emerge should
the trials be successful. ‘At present our
focus is on preventing HIV infection,
nothing else,’ he said.
Johansson said his centre hoped to
begin with three more microbicide gel
trials in South Africa next year. These
were called Tro2000 – very similar to
Buffergel, which changed the pH in the
vagina to become unfriendly to the
virus, and Cellulose Sulphate, which
bound the virus in a manner similar to
Carraguard.
‘It’s not always nice to be a world
leader in this kind of research because
everyone else learns from our mistakes,’
he quipped.
Changing women’s lives
He emphasised that an effective
microbicide would be the first socially
acceptable prophylactic product that
women could use themselves.
Condoms were very effective when
used consistently and properly.
However, unless they were viewed in
‘a more epidemiological way ‘ that took
into account the low status and lack of
sexual negotiating power of women,
their efficacy was dangerously
exaggerated.
Govender said his team would begin
analysing the data next year and
‘hopefully by 2007, give or take a couple
of months, we’ll have solid results’.
Chris Bateman
Results in animals
showed that the gel
protected monkeys against
SIV, rats against herpes
simplex, while a special
system in which tissue from
the human vagina was
transplanted into animals
had also proved successful.
